Letrozole Evolugen

Letrozole, the active ingredient in Letrozole Evolugen, is an aromatase inhibitor presented as an oral tablet for oral use. It belongs to the antineoplastic hormone therapy class and selectively inhibits estrogen synthesis, reducing circulating estrogen levels. The medication is prescribed for hormone receptor‑positive breast cancer in postmenopausal women and is taken under medical supervision.

GNH USA supplies Letrozole Evolugen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, ensuring product quality, traceability and regulatory compliance for global distribution.

Letrozole Evolugen is an aromatase inhibitor used in the management of breast cancer that depends on estrogen signaling.

Hormone receptor‑positive breast cancer (early stage): reduces recurrence risk when given as adjuvant therapy. Metastatic breast cancer: slows disease progression in postmenopausal patients. Adjuvant therapy for early‑stage disease: improves disease‑free survival after surgery.

Letrozole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Hot flashes: sudden feeling of warmth and sweating. - Joint or muscle pain: aching in limbs or back. - Fatigue: persistent tiredness. - Nausea: upset stomach, sometimes with vomiting. - Headache: mild to moderate intensity. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Bone fractures: increased risk of osteoporosis‑related breaks. - Deep vein thrombosis or pulmonary embolism: clot formation in veins. - Severe liver injury: jaundice, elevated enzymes. - Allergic reactions: rash, swelling, anaphylaxis. - Elevated cholesterol: significant lipid changes. - Cardiovascular events: heart attack or stroke in susceptible patients.

Before initiating Letrozole therapy, clinicians should evaluate patient‑specific risk factors.

Monitor bone density: assess osteoporosis risk and consider supplementation. Assess liver function: obtain baseline tests and repeat periodically. Check cardiovascular status: watch for signs of thromboembolic disease. Avoid use in pregnancy: drug is contraindicated for pregnant women. Store below 25°C: keep in the original pack, protect from moisture and direct sunlight.

Letrozole can interact with several medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Concurrent estrogen replacement therapy: antagonizes Letrozole’s action. - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce plasma concentrations. - Strong CYP2C19 inhibitors (e.g., fluconazole): can increase Letrozole exposure.

Moderate Interactions (Monitor Closely): - Tamoxifen: Letrozole may diminish its metabolic activation. - Warfarin: enhanced anticoagulant effect, requiring INR monitoring. - Statins: potential increase in statin‑related muscle toxicity.